Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01172691 · ClinicalTrials.gov registry record · Phase 2
Trial of Inhaled Nitric Oxide (iNO) on Ischemia / Reperfusion Injury During Orthotopic Liver Transplantation With Marginal Grafts
A Phase 2 study, sponsored by Baylor Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT01172691 is a Phase 2 study that has completed, run by Baylor Research Institute. The registered enrollment target is 23 participants.
The verdict
NCT01172691, a Phase 2 study, has completed, sponsored by Baylor Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
This study is being done to determine if patients receiving (iNO) will have increased liver function and less damage from IR than patients who do not receive (iNO).
Interventions
- DRUG Inhaled Nitric Oxide (iNO)
- DRUG Placebo Arm (Nitrogen)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2010-07 |
| Est. Completion | 2014-01-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01172691
The ClinicalTrials.gov registry entry for NCT01172691 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor Research Institute, which has 180 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Inhaled Nitric Oxide (iNO) is the first listed.
NCT01172691 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01172691 about?
NCT01172691 is a clinical study titled "Trial of Inhaled Nitric Oxide (iNO) on Ischemia / Reperfusion Injury During Orthotopic Liver Transplantation With Marginal Grafts". This study is being done to determine if patients receiving (iNO) will have increased liver function and less damage from IR than patients who do not receive (iNO).
What is the current status of trial NCT01172691?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2010-07. Estimated completion is 2014-01-22.
What interventions are being tested in trial NCT01172691?
The interventions under investigation include: Inhaled Nitric Oxide (iNO) (DRUG), Placebo Arm (Nitrogen) (DRUG).
Who is sponsoring clinical trial NCT01172691?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.